Blood Biomarkers of Alzheimer's Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

Interventions targeting lifestyle and health behaviors support cognition in older adults at risk of dementia. It remains unclear if the cognitive benefit of such interventions is modified by Alzheimer's disease (AD)-related neuropathology, and if lifestyle interventions lead to changes in blood AD biomarkers. Here, we analyzed core AD plasma biomarkers (A{beta}, p-tau181, p-tau217, p-tau231, NFL, GFAP) in the two-year FINGER randomized controlled multidomain lifestyle trial, which demonstrated cognitive efficacy in an at-risk older general population (N=1260). We found that 85% of participants

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.